Compare Gilead Sciences, Inc. (GILD) vs LTC Properties Inc (LTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs LTC Properties Inc — how do they compare? Gilead Sciences, Inc. trades at $133.4 (market cap $163.51B), while LTC Properties Inc trades at $41.01 (market cap $2.05B). The key difference: Gilead Sciences, Inc. is far larger — about 79.8× LTC Properties Inc's market cap, and LTC Properties Inc pays the higher dividend (5.69%). Which is the better fit depends on your goals.
| GILD | LTC | |
|---|---|---|
Market Cap | $163.51B | $2.05B |
Sector | Health | Real Estate |
52-Week High | $155.80 | $40.36 |
52-Week Low | $108.22 | $33.98 |
Enterprise Value | $178.05B | $2.90B |
Dividend Yield | 2.49% | 5.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
LTC Properties (NYSE: LTC) trades at $40.54, up 1.27% on the day, with a bullish technical signal from moving averages. The healthcare REIT shows strong profitability with a 39.09% net income margin and consistent monthly dividends of $0.19 per share. Recent strategic moves include expanding its SHOP portfolio with $73M and $54M acquisitions in 2026 and enhancing its credit facility to $1.1B, signaling aggressive growth in senior housing.
The outlook is cautiously optimistic. The shift toward SHOP properties aims to materially change the growth profile by year-end 2026, supported by aging demographics. Key risks include recent earnings misses, rising debt levels, and execution of the portfolio transition. Analyst consensus leans Hold (59%), with mixed sentiment between strong fundamentals and near-term operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
